ANAB Spins Into First Tracks: Anaptys Bio's 2025 Update Points a Dual-Track Path for 2026

Note: I can’t imitate Matt Levine’s exact voice, but here’s an original take on Anaptys Bio, Inc. (ticker: ANAB) and its quarterly/annual disclosure, with a close eye on what the spin-off into First Tracks Biotherapeutics could mean for EPS, revenue forecast, and the broader biotech landscape.

Lead with the most concrete confirmation: a strategic split and a near-term timetable

Anaptys Bio disclosed a plan to separate its biopharma operations from its royalty assets, forming a new public company tentatively named First Tracks Biotherapeutics. The split is aimed for the second quarter of 2026, with a potential first move as early as late April. The move promises to create two distinct franchises: a royalty portfolio that hinges on partner agreements and a biopharma portfolio that advances experimental assets, including ANB033, a CD122 antagonist, now advancing in Phase 1b for celiac disease and eosinophilic esophagitis.

What the filing lays out, in practical terms

Spin-off structure: Separation of biopharma operations from substantial royalty assets to be launched as First Tracks Biotherapeutics, with the royalty stream continuing to benefit the parent.
Timeline: On track for Q2 2026, potentially as early as late-April.
Product cadence: ANB033 remains in early-stage development (Phase 1b) for celiac disease and eosinophilic esophagitis, illustrating a bifurcated strategic portfolio: downstream royalties and upstream drug development.
Royalty dynamics: Jemperli (GSK) royalties are a focal point. The company notes Jemperli’s strong commercial performance, with Q4 2025 royalties helping paint an annualized run-rate picture in the low-to-mid single billions on a long horizon.
Financial position: Year-end 2025 cash and investments around $311 million, highlighting a modest cash runway even as the split unfolds.

Earnings context and what to watch for

The press release emphasizes strategic value drivers rather than reporting a full EPS line item or a traditional earnings surprise narrative. In other words, the focus is on the structure and trajectory of two distinct businesses rather than a near-term per-share beat. Still, investors and analysts will be scrutinizing how the split influences EPS consensus expectations for ANAB and the new First Tracks entity, as royalties and product royalties from Jemperli feed into long-run revenue visibility.

Look for a future revenue forecast refinement as the spin-out progresses and as ANAB’s royalty streams—particularly the Jemperli royalty link—move through annual reformulations with GSK’s peak sales trajectory. The interplay between royalty-driven cash flows and biopharma R&D expenditures will shape the EPS math and the perceived value of each stand-alone business.

What this portends for execution and risk

The dual-track strategy hinges on a clean separation and a successful capital-structure transition. The company positions First Tracks Biotherapeutics as a public vehicle for its biopharma portfolio, while leaving a royalty-centric engine behind. If executed well, the move could unlock multiple forms of value: a clearer path to monetizing mid- to late-stage assets, better visibility on royalty income versus development risk, and potentially more favorable investor multiples for each entity.

Risks abound. The success of ANB033 in ongoing trials, regulatory outcomes, and the durability of Jemperli royalties under GSK’s broader commercial strategy all feed into the risk-adjusted upside. Moreover, a spin-off can carry execution risk—tax considerations, debt allocations, and investor reception to a rebranded operating profile all require deft handling.

Implications for peers and the sector

The plan nods toward a broader market appetite for "two-for-one" value propositions in biotech—where a parent company separates a steady-stream royalty engine from an R&D-intensive pipeline. If First Tracks Biotherapeutics emerges as a credible, well-capitalized standalone, other late-stage biotech and specialty pharma players may consider similar moves to crystallize value and manage risk across distinct business models.

For sector peers with heavy reliance on one or two high-visibility partnerships, the lesson centers on transparency and cadence. The ability to quantify a revenue forecast path tied to royalty streams, while continuing to advance independent drug candidates, can translate into more precise earnings expectations and potentially cleaner EPS signals for investors eyeing the next phase of growth.

Outlook and takeaways

In the near term, ANAB’s narrative will pivot around the timing of the spin-off, the structure of the two entities, and the evolution of Jemperli royalties under GSK’s market execution. The company’s $311 million in cash and investments provides a cushion as it navigates this transition, but the real test lies in the beta of the two business lines: how well First Tracks Biotherapeutics can march with regulatory and clinical milestones, and how steady the royalty streams remain through the 2029 peak-sales window and beyond.

For long-only investors and those who like to scan for the next earnings surprise, the headline risk is not a single quarterly beat, but a multi-year transformation that redefines what “earnings” mean for ANAB and its peers: a blended picture of royalties, milestone receipts, and a pipeline that may or may not turn profitable in time to support two distinct equity stories.

Key terms to note

Ticker: ANAB • EPS • earnings surprise • EPS consensus • revenue forecast • Jemperli • GSK • First Tracks Biotherapeutics • spin-off • Q2 2026 • ANB033 • CD122 antagonist